NUR-641E ADVANCED PATHOPHYSIOLOGY & PHARMACOLOGY
- 2026/2027 ACADEMIC YEAR - COMPREHENSIVE MIDTERM
PRACTICE QUESTION BANK WITH RATIONALES AND
DISTRACTOR ANALYSIS
160 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NUR-641E ADVANCED PATHOPHYSIOLOGY & PHARMACOLOGY - 2026/2027 ACADEMIC YEAR -
COMPREHENSIVE MIDTERM PRACTICE QUESTION BANK WITH RATIONALES AND DISTRACTOR
ANALYSIS. It contains 160 carefully selected questions that reflect the most current exam content and testing
strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 160 Questions
Foundations - Application - Nur-641e Advanced Pathophysiology & Pharmacology 2026/2027 Academic
YEAR Comprehensive BANK WITH Rationales AND Distractor Analysis Advanced Pathophysiology &
Pharmacology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Nur-641e Advanced 1-27 Chronic, Mechanism, Disease, Explains, Heart Failure
Pathophysiology &
Pharmacology 2026/2027
Academic YEAR
Comprehensive BANK WITH
Rationales AND Distractor
Analysis Advanced
Pathophysiology &
Pharmacology Graduate
Chronic 28-54 Mechanism, Explains, Acute, Kidney, Disease
Explains 55-81 Mechanism, Kidney, Develops, Chronic, Describes
Disease 82-108 Mechanism, Chronic, Kidney Disease, Started, Therapy
Kidney 109-135 Mechanism, Chronic, Explains, Disease, Prescribed
Prescribed 136-160 Chronic, Mechanism, Effect, Explains, Disease
TOTAL 160 All questions include answers and detailed rationales
,Section A - Nur-641e Advanced Pathophysiology &
Pharmacology 2026/2027 Academic YEAR Comprehensive
BANK WITH Rationales AND Distractor Analysis Advanced
Pathophysiology & Pharmacology Graduate
Q1.
In a patient with chronic heart failure, which neurohormonal adaptation initially
compensates but ultimately contributes to disease progression by promoting adverse
cardiac remodeling?
A. Activation of the B. Upregulation of -adrenergic receptors
renin-angiotensin-aldosterone system
(RAAS)
C. Increased release of atrial natriuretic D. Enhanced parasympathetic tone
peptide (ANP)
Correct: A - Activation of the renin-angiotensin-aldosterone system (RAAS)
Rationale:Chronic RAAS activation increases afterload and promotes myocardial fibrosis and
remodeling, worsening heart failure. -receptor downregulation (not upregulation) occurs, and
ANP is compensatory but not maladaptive. Parasympathetic tone is reduced in heart failure.
Q2.
A patient on warfarin develops a supratherapeutic INR with major bleeding. Which
pharmacologic agent directly reverses the anticoagulant effect by restoring functional
vitamin K-dependent clotting factors?
A. Protamine sulfate B. Phytonadione (vitamin K1)
C. Tranexamic acid D. Desmopressin
Correct: B - Phytonadione (vitamin K1)
Rationale:Phytonadione is the specific antidote for warfarin, as it enables synthesis of vitamin
K-dependent factors. Protamine reverses heparin, not warfarin. Tranexamic acid and
desmopressin are hemostatic agents but do not reverse warfarin's effect.
Q3.
Which pathophysiologic mechanism best explains the development of hyperkalemia in a
patient with chronic kidney disease (CKD) stage 4?
A. Increased aldosterone secretion B. Reduced tubular secretion of potassium
in the distal nephron
Page 3
, Section A - Nur-641e Advanced Pathophysiology & Pharmacology 2026/2027 Academic YEAR Comprehensive BANK WITH Rationales AND
Distractor Analysis Advanced Pathophysiology & Pharmacology Graduate
C. Enhanced Na+/K+-ATPase activity in D. Decreased dietary potassium intake
skeletal muscle
Correct: B - Reduced tubular secretion of potassium in the distal nephron
Rationale:In CKD, reduced nephron mass impairs potassium secretion in the distal tubule,
leading to hyperkalemia. Aldosterone is often decreased (or ineffective) in CKD, and
Na+/K+-ATPase activity is not enhanced. Decreased intake would lower, not raise,
potassium.
Q4.
A patient with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min) requires an
antihyperglycemic agent. Which medication requires no dose adjustment and is preferred
due to cardiovascular benefits?
A. Metformin B. Empagliflozin
C. Glyburide D. Pioglitazone
Correct: B - Empagliflozin
Rationale:Empagliflozin is an SGLT2 inhibitor that is effective at low eGFR and provides
cardiorenal benefits; it does not require dose adjustment. Metformin is contraindicated when
eGFR <30. Glyburide is avoided due to hypoglycemia risk in CKD. Pioglitazone can cause
fluid retention and is not preferred.
Q5.
Which of the following best describes the primary mechanism of action of loop diuretics
in the treatment of acute pulmonary edema?
A. Inhibition of the Na+-K+-2Cl cotransporter B. Blockade of the epithelial sodium channel
in the thick ascending limb of the loop of in the collecting duct
Henle
C. Antagonism of aldosterone receptors in D. Inhibition of carbonic anhydrase in the
the distal tubule proximal tubule
Correct: A - Inhibition of the Na+-K+-2Cl cotransporter in the thick ascending limb of the
loop of Henle
Rationale:Loop diuretics (e.g., furosemide) inhibit the Na+-K+-2Cl" cotransporter in the thick
ascending limb, producing potent diuresis. ENaC blockade (amiloride) and aldosterone
antagonism (spironolactone) are weak. Carbonic anhydrase inhibitors (acetazolamide) are
weak and proximal.
Page 4
- 2026/2027 ACADEMIC YEAR - COMPREHENSIVE MIDTERM
PRACTICE QUESTION BANK WITH RATIONALES AND
DISTRACTOR ANALYSIS
160 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NUR-641E ADVANCED PATHOPHYSIOLOGY & PHARMACOLOGY - 2026/2027 ACADEMIC YEAR -
COMPREHENSIVE MIDTERM PRACTICE QUESTION BANK WITH RATIONALES AND DISTRACTOR
ANALYSIS. It contains 160 carefully selected questions that reflect the most current exam content and testing
strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 160 Questions
Foundations - Application - Nur-641e Advanced Pathophysiology & Pharmacology 2026/2027 Academic
YEAR Comprehensive BANK WITH Rationales AND Distractor Analysis Advanced Pathophysiology &
Pharmacology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Nur-641e Advanced 1-27 Chronic, Mechanism, Disease, Explains, Heart Failure
Pathophysiology &
Pharmacology 2026/2027
Academic YEAR
Comprehensive BANK WITH
Rationales AND Distractor
Analysis Advanced
Pathophysiology &
Pharmacology Graduate
Chronic 28-54 Mechanism, Explains, Acute, Kidney, Disease
Explains 55-81 Mechanism, Kidney, Develops, Chronic, Describes
Disease 82-108 Mechanism, Chronic, Kidney Disease, Started, Therapy
Kidney 109-135 Mechanism, Chronic, Explains, Disease, Prescribed
Prescribed 136-160 Chronic, Mechanism, Effect, Explains, Disease
TOTAL 160 All questions include answers and detailed rationales
,Section A - Nur-641e Advanced Pathophysiology &
Pharmacology 2026/2027 Academic YEAR Comprehensive
BANK WITH Rationales AND Distractor Analysis Advanced
Pathophysiology & Pharmacology Graduate
Q1.
In a patient with chronic heart failure, which neurohormonal adaptation initially
compensates but ultimately contributes to disease progression by promoting adverse
cardiac remodeling?
A. Activation of the B. Upregulation of -adrenergic receptors
renin-angiotensin-aldosterone system
(RAAS)
C. Increased release of atrial natriuretic D. Enhanced parasympathetic tone
peptide (ANP)
Correct: A - Activation of the renin-angiotensin-aldosterone system (RAAS)
Rationale:Chronic RAAS activation increases afterload and promotes myocardial fibrosis and
remodeling, worsening heart failure. -receptor downregulation (not upregulation) occurs, and
ANP is compensatory but not maladaptive. Parasympathetic tone is reduced in heart failure.
Q2.
A patient on warfarin develops a supratherapeutic INR with major bleeding. Which
pharmacologic agent directly reverses the anticoagulant effect by restoring functional
vitamin K-dependent clotting factors?
A. Protamine sulfate B. Phytonadione (vitamin K1)
C. Tranexamic acid D. Desmopressin
Correct: B - Phytonadione (vitamin K1)
Rationale:Phytonadione is the specific antidote for warfarin, as it enables synthesis of vitamin
K-dependent factors. Protamine reverses heparin, not warfarin. Tranexamic acid and
desmopressin are hemostatic agents but do not reverse warfarin's effect.
Q3.
Which pathophysiologic mechanism best explains the development of hyperkalemia in a
patient with chronic kidney disease (CKD) stage 4?
A. Increased aldosterone secretion B. Reduced tubular secretion of potassium
in the distal nephron
Page 3
, Section A - Nur-641e Advanced Pathophysiology & Pharmacology 2026/2027 Academic YEAR Comprehensive BANK WITH Rationales AND
Distractor Analysis Advanced Pathophysiology & Pharmacology Graduate
C. Enhanced Na+/K+-ATPase activity in D. Decreased dietary potassium intake
skeletal muscle
Correct: B - Reduced tubular secretion of potassium in the distal nephron
Rationale:In CKD, reduced nephron mass impairs potassium secretion in the distal tubule,
leading to hyperkalemia. Aldosterone is often decreased (or ineffective) in CKD, and
Na+/K+-ATPase activity is not enhanced. Decreased intake would lower, not raise,
potassium.
Q4.
A patient with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min) requires an
antihyperglycemic agent. Which medication requires no dose adjustment and is preferred
due to cardiovascular benefits?
A. Metformin B. Empagliflozin
C. Glyburide D. Pioglitazone
Correct: B - Empagliflozin
Rationale:Empagliflozin is an SGLT2 inhibitor that is effective at low eGFR and provides
cardiorenal benefits; it does not require dose adjustment. Metformin is contraindicated when
eGFR <30. Glyburide is avoided due to hypoglycemia risk in CKD. Pioglitazone can cause
fluid retention and is not preferred.
Q5.
Which of the following best describes the primary mechanism of action of loop diuretics
in the treatment of acute pulmonary edema?
A. Inhibition of the Na+-K+-2Cl cotransporter B. Blockade of the epithelial sodium channel
in the thick ascending limb of the loop of in the collecting duct
Henle
C. Antagonism of aldosterone receptors in D. Inhibition of carbonic anhydrase in the
the distal tubule proximal tubule
Correct: A - Inhibition of the Na+-K+-2Cl cotransporter in the thick ascending limb of the
loop of Henle
Rationale:Loop diuretics (e.g., furosemide) inhibit the Na+-K+-2Cl" cotransporter in the thick
ascending limb, producing potent diuresis. ENaC blockade (amiloride) and aldosterone
antagonism (spironolactone) are weak. Carbonic anhydrase inhibitors (acetazolamide) are
weak and proximal.
Page 4
